Seroquel approved for Maintenance Treatment in Bipolar Disorder « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
May 2008

M T W T F S S

« Apr Jun »

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30 31

Seroquel approved for Maintenance Treatment in Bipolar Disorder

Posted on May 14, 2008 by crimsoncanary

The FDA has approved Seroquel (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder. Seroquel is already approved by the FDA for the treatment of schizophrenia

Filed under: gpcr | Tagged: 5-HT1A, 5-HT2, 5HT1A, 5HT2, Alpha 1 Adrenoceptor, Alpha 2 Adrenoceptor, antagonist, Approval, Astrazeneca, Dopamine D1, Dopamine D2, gpcr, Histamine H1

« Pozen transfer IND/NDA for Treximet to GSK Exforge treatment effective in black patients »

Leave a Reply